Ads
related to: bortezomib and multiple myeloma treatment options
Search results
Results From The WOW.Com Content Network
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. [4] This includes multiple myeloma in those who have and have not previously received treatment. [3] It is generally used together with other medications. [3] It is given by injection. [4]
Bortezomib (Velcade) was approved in 2003. This was the first proteasome inhibitor approved for use in the U.S. Its boron atom binds the catalytic site of the 26S proteasome. [20] Carfilzomib (Kyprolis) was approved by the FDA for relapsed and refractory multiple myeloma in 2012 . [21]
Bortezomib/dexamethasone is a combination drug against multiple myeloma. [1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid.
A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107] There are two types of stem cell transplants to treat multiple myeloma. [108] In autologous hematopoietic stem-cell transplantation (ASCT) – the patient's stem cells are collected from the patient's blood. The patient is given high-dose ...
cyclophosphamide, bortezomib, dexamethasone: multiple myeloma, AL amyloidosis DA or DAC: daunorubicin x 3 days plus ara-C x 7 days, a variant of 7+3 regimen Acute myeloid leukemia, excluding acute promyelocytic leukemia: DAT: daunorubicin, cytarabine (ara-C), tioguanine: Acute myeloid leukemia: DCEP
Prince William was forced to cancel a royal outing on Thursday, Jan. 16.. The Prince of Wales, 42, was planning to visit families and servicemen and women at a military regiment where he holds a ...
Ads
related to: bortezomib and multiple myeloma treatment options